(Q38096424)

28 August 2017

title

Cetuximab: still an option in the treatment of pancreatic cancer? (English)

1 reference

28 August 2017

1 reference

Luca Faloppi

1

1 reference

28 August 2017

Kalliopi Andrikou

series ordinal

2

1 reference

28 August 2017

Stefano Cascinu

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

791-801

1 reference

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

The epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Cetuximab in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

The role of the EGFR signaling in tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786697

10.1517/14712598.2013.786697

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference